Dosing & Administration of PROLASTIN-C

PROLASTIN-C is a medicine that is given through a needle into a vein. While it is a prescription medicine, PROLASTIN-C is not a prescription you pick up at your pharmacy. PROLASTIN-C is shipped directly to you, to your doctor, or to an infusion center authorized by you and your doctor.1

The dosing of PROLASTIN-C is based on how much you weigh. The recommended dose is 60 milligrams for each kilogram (2.2 pounds) of your body weight given once a week.1

You can receive PROLASTIN-C at a rate of up to 0.08 milliliters for each kilogram per minute. The average infusion takes about 15 minutes to infuse.1

Get Adobe Reader

No refrigeration necessary

PROLASTIN-C does not need to be refrigerated and can be stored at room temperature, but the temperature should not exceed 25°C (77°F). You should also avoid freezing PROLASTIN-C because the bottle holding the diluent (sterile water) might break.1

PROLASTIN DIRECT® PATIENT SERVICES

One-stop PROLASTIN-C enrollment, delivery and support.

Prolastin Direct® Patient Services secures insurance authorization, coordinates infusion services, ships PROLASTIN-C directly to the location of your choice, and connects you to health management coordinators who are experienced Alpha-1 patients themselves. Find out more about Prolastin Direct® Patient Services now.


PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


References

  1. PROLASTIN-C [package insert]. Grifols